Long-lasting severe immune dysfunction in Ebola virus disease survivors.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
24 07 2020
Historique:
received: 05 09 2019
accepted: 29 06 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 9 9 2020
Statut: epublish

Résumé

Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18-25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in 'inflammation' and 'antiviral' pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of "chronic Ebola virus disease (CEVD)".

Identifiants

pubmed: 32709840
doi: 10.1038/s41467-020-17489-7
pii: 10.1038/s41467-020-17489-7
pmc: PMC7381622
doi:

Substances chimiques

Antibodies, Viral 0
Antiviral Agents 0
Cytokines 0
Genetic Markers 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3730

Investigateurs

Ahidjo Ayouba (A)
Eric Delaporte (E)
Alpha Kabinet Keita (AK)
Lamine Koivogui (L)
Christine Lacabaratz (C)
Claire Levy Marchal (CL)
Yves Levy (Y)
Hervé Raoul (H)
Abdoulaye Touré (A)

Références

WHO. Ebola Data and Statistics. Situation Summary. http://apps.who.int/gho/data/view.ebola-sitrep.ebola-summary-20160511?lang=en (2016).
Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371, 1418–1425 (2014).
pubmed: 24738640
Etard, J.-F. et al. Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect. Dis. 17, 545–552 (2017).
pubmed: 28094208
Group, P. I. S. et al. A longitudinal study of Ebola sequelae in Liberia. N. Engl. J. Med. 380, 924–934 (2019).
Msellati, P. et al. Revival after Ebola: multidisciplinary assessment at 1 year, prospect and follow-up study of surviving patients from Ebola in Guinea (PostEboGui cohort)]. Bull. Soc. Pathol. Exot. 109, 236–243 (2016).
pubmed: 27704472
Bwaka, M. A. et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis. 179, S1–S7 (1999).
pubmed: 9988155
Kibadi, K. et al. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J. Infect. Dis. 179, S13–S14 (1999).
pubmed: 9988158
Rodriguez, L. L. et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179, S170–S176 (1999).
pubmed: 9988181
Rowe, A. K. et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J. Infect. Dis. 179, S28–S35 (1999).
pubmed: 9988162
Mattia, J. G. et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect. Dis. 16, 331–338 (2016).
pubmed: 26725449
McElroy, A. K. et al. Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. USA 112, 4719–4724 (2015).
pubmed: 25775592
Ruibal, P. et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 533, 100–104 (2016).
pubmed: 27147028 pmcid: 4876960
Dahlke, C. et al. Comprehensive characterization of cellular immune responses following Ebola virus infection. J. Infect. Dis. 215, 287–292 (2017).
pubmed: 27799354
Kash, J. C. et al. Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. Sci. Transl. Med. 9, https://doi.org/10.1126/scitranslmed.aai9321 (2017).
Kerber, R. et al. Kinetics of soluble mediators of the host response in Ebola virus disease. J. Infect. Dis. 218, S496–S503 (2018).
pubmed: 30101349 pmcid: 6249596
Colavita, F. et al. Inflammatory and humoral immune response during Ebola virus infection in survivor and fatal cases occurred in Sierra Leone during the 2014–2016 outbreak in West Africa. Viruses 11, https://doi.org/10.3390/v11040373 (2019).
Reynard, S. et al. Immune parameters and outcomes during Ebola virus disease. JCI Insight 4, https://doi.org/10.1172/jci.insight.125106 (2019).
Keita A.K. et al. A 40 months follow-up of Ebola virus disease survivors in Guinea (Postebogui) reveals longterm detection of Ebola viral RNA in semen and breast milk. Open Forum Infect. Dis. 6, https://doi.org/10.1093/ofid/ofz482 (2019).
Caradonna, L. et al. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr. Pharm. Des. 8, 995–1005 (2002).
pubmed: 11945146
Brenchley, J. M. & Douek, D. C. The mucosal barrier and immune activation in HIV pathogenesis. Curr. Opin. HIV AIDS 3, 356–361 (2008).
pubmed: 19372990 pmcid: 2789390
Marchetti, G., Tincati, C. & Silvestri, G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin. Microbiol. Rev. 26, 2–18 (2013).
pubmed: 23297256 pmcid: 3553668
Klatt, N. R., Funderburg, N. T. & Brenchley, J. M. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 21, 6–13 (2013).
pubmed: 23062765
Olsen, P. S. Role of epidermal growth-factor in gastroduodenal mucosal protection. J. Clin. Gastroenterol. 10, S146–S151 (1988).
Reed, D. S., Hensley, L. E., Geisbert, J. B., Jahrling, P. B. & Geisbert, T. W. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic fever in Cynomolgus macaques. Viral Immunol. 17, 390–400 (2004).
pubmed: 15357905
Gupta, M., Spiropoulou, C. & Rollin, P. E. Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology 364, 45–54 (2007).
pubmed: 17391724
Menicucci, A. R. et al. Transcriptome analysis of circulating immune cell subsets highlight the role of monocytes in Zaire Ebola Virus Makona pathogenesis. Front. Immunol. 8, 1372 (2017).
pubmed: 29123522 pmcid: 5662559
Geisbert, T. W. et al. Pathogenesis of Ebola hemorrhagic fever in primate models. Am. J. Pathol. 163, 2371–2382 (2003).
pubmed: 14633609 pmcid: 1892396
Chaussabel, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29, 150–164 (2008).
pubmed: 18631455 pmcid: 2727981
Liu, X. et al. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol. 18, 4 (2017).
pubmed: 28100256 pmcid: 5244546
Gonzalez, V. D. et al. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J. Immunol. 183, 6612–6618 (2009).
pubmed: 19846870
Milush, J. M. et al. CD56negCD16(+) NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology 10, 158 (2013).
pubmed: 24351015 pmcid: 3892122
Cimini, E. et al. Different features of Vdelta2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Negl. Trop. Dis. 11, e0005645 (2017).
pubmed: 28558022 pmcid: 5472323
Schieffelin, J. S. et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N. Engl. J. Med. 371, 2092–2100 (2014).
pubmed: 25353969 pmcid: 4318555
Hunt, L. et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect. Dis. 15, 1292–1299 (2015).
pubmed: 26271406
Monticelli, L. A. et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc. Natl. Acad. Sci. USA 112, 10762–10767 (2015).
pubmed: 26243875
Williamson, L. E. et al. Early human B cell response to Ebola virus in four U.S. survivors of infection. J. Virol. 93, https://doi.org/10.1128/JVI.01439-18 (2019).
Rimoin, A. W. et al. Ebola virus neutralizing antibodies detectable in survivors of the Yambuku, Zaire outbreak 40 years after infection. J. Infect. Dis. 217, 223–231 (2018).
pubmed: 29253164
Sobarzo, A. et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J. Infect. Dis. 208, 299–309 (2013).
pubmed: 23585686
Davis, C. W. et al. Longitudinal analysis of the human B cell response to Ebola virus infection. Cell 177, e1517 (2019).
Varkey, J. B. et al. Persistence of Ebola virus in ocular fluid during convalescence. N. Engl. J. Med. 372, 2423–2427 (2015).
pubmed: 25950269 pmcid: 4547451
Diallo, B. et al. Resurgence of Ebola virus disease in guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin. Infect. Dis. 63, 1353–1356 (2016).
pubmed: 27585800 pmcid: 5091350
Deen, G. F. et al. Ebola RNA persistence in semen of Ebola virus disease survivors–final report. N. Engl. J. Med. 377, 1428–1437 (2017).
pubmed: 26465681
Sow, M. S. et al. New evidence of long-lasting persistence of Ebola virus genetic material in semen of survivors. J. Infect. Dis. 214, 1475–1476 (2016).
pubmed: 27142204
Ayouba, A. et al. Development of a sensitive and specific serological assay based on luminex technology for detection of antibodies to Zaire Ebola Virus. J. Clin. Microbiol. 55, 165–176 (2017).
pubmed: 27795350
Keita, A. K. et al. Serological evidence of Ebola virus infection in rural Guinea before the 2014 West African epidemic outbreak. Am. J. Trop. Med. Hyg. 99, 425–427 (2018).
pubmed: 29869602 pmcid: 6090347
See, P. et al. Mapping the human DC lineage through the integration of high-dimensional techniques. Science 356, https://doi.org/10.1126/science.aag3009 (2017).
Chujo, D. et al. ZnT8-zpecific CD4+ T cells display distinct cytokine expression profiles between type 1 diabetes patients and healthy adults. PLoS ONE 8, e55595 (2013).
pubmed: 23390544 pmcid: 3563599
Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytom. A 79, 167–174 (2011).

Auteurs

Aurélie Wiedemann (A)

INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.

Emile Foucat (E)

INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.

Hakim Hocini (H)

INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.

Cécile Lefebvre (C)

INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.

Boris P Hejblum (BP)

Department of Public Health, Inserm Bordeaux Population Health Research Centre, Univ. Bordeaux, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI), Créteil, France.

Mélany Durand (M)

Department of Public Health, Inserm Bordeaux Population Health Research Centre, Univ. Bordeaux, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI), Créteil, France.

Miriam Krüger (M)

Department of Public Health, Inserm Bordeaux Population Health Research Centre, Univ. Bordeaux, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI), Créteil, France.

Alpha Kabinet Keita (AK)

TransVIHMI, IRD UMI 233, INSERM U1175, Montpellier University, Montpellier, France.
CERFIG, Gamal Nasser University, Conakry, Guinea.

Ahidjo Ayouba (A)

TransVIHMI, IRD UMI 233, INSERM U1175, Montpellier University, Montpellier, France.

Stéphane Mély (S)

Laboratoire P4 Inserm-Jean Mérieux, US003 INSERM, Lyon, France.

José-Carlos Fernandez (JC)

INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.

Abdoulaye Touré (A)

TransVIHMI, IRD UMI 233, INSERM U1175, Montpellier University, Montpellier, France.
CERFIG, Gamal Nasser University, Conakry, Guinea.
Institut National de Santé Publique (INSP), Conakry, Guinea.

Slim Fourati (S)

Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Laboratoire de Virologie, Créteil, France.

Claire Lévy-Marchal (C)

Pôle de Recherche Clinique (PRC), INSERM, Paris, France.

Hervé Raoul (H)

Laboratoire P4 Inserm-Jean Mérieux, US003 INSERM, Lyon, France.

Eric Delaporte (E)

TransVIHMI, IRD UMI 233, INSERM U1175, Montpellier University, Montpellier, France.

Lamine Koivogui (L)

Institut National de Santé Publique (INSP), Conakry, Guinea.

Rodolphe Thiébaut (R)

Department of Public Health, Inserm Bordeaux Population Health Research Centre, Univ. Bordeaux, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI), Créteil, France.
CHU Bordeaux, Bordeaux, France.

Christine Lacabaratz (C)

INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, Créteil, France.

Yves Lévy (Y)

INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, Créteil, France. yves.levy@aphp.fr.
Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France. yves.levy@aphp.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH